<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112316</url>
  </required_header>
  <id_info>
    <org_study_id>833681r</org_study_id>
    <secondary_id>1R61HL146390-01</secondary_id>
    <nct_id>NCT04112316</nct_id>
  </id_info>
  <brief_title>Developing Oral LT3 Therapy for Heart Failure - HFrEF</brief_title>
  <acronym>DOT3HF-HFrEF</acronym>
  <official_title>Developing Oral LT3 Therapy For Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy
      with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction
      (HFrEF) and low triiothyronine (T3) syndrome by conducting a randomized, double-blind,
      placebo-controlled cross-over study with a two week washout period between treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal is to determine the safety, feasibility, and preliminary efficacy of
      administering oral LT3 therapy in the study population of participants with heart failure
      with reduced ejection fraction (HFrEF). Each treatment period will be approximately 8 weeks
      in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose
      for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug). LT3
      will be titrated to T3 levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigators and Care Providers are blinded to LT3 vs. Placebo and T3 results. There will be 1 unblinded physician in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment</measure>
    <time_frame>continuous during intervention (14 days)</time_frame>
    <description>Percent increase (atrial fibrillation, ventricular tachycardia, supraventricular and ventricular) ectopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T3 Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of participant T3 levels above upper limit of reference range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change peak rate of oxygen consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Kansas City Cardiomyopathy Questionnaire, KCCQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in remotely sensed difference in counts per minute (CPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in B-type natriuretic peptide, Pg/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Low Triiodothyronine Syndrome</condition>
  <arm_group>
    <arm_group_label>Liothyronine (LT3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liothyronine or placebo</intervention_name>
    <description>Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.</description>
    <arm_group_label>Liothyronine (LT3)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women aged ≥18 years

          2. NYHA Class I, II or III heart failure

          3. EF≤40 percent within the past year

          4. An implantable cardioverter-defibrillator (ICD)

          5. Stable doses of neurohormonal blockade for 30 days

          6. TSH and free T4 level within the laboratory reference range and total T3 level &lt;94
             ng/dL

        Exclusion Criteria:

          1. Hypertrophic or restrictive cardiomyopathy

          2. Uncorrected severe primary valvular disease

          3. Arrhythmia that results in irregular heart rate

          4. Inability to perform VO2max exercise testing

          5. Severe lung disease, including treatment with oral steroids within past 6 months for
             exacerbation of obstructive lung disease or use of daytime supplemental oxygen

          6. Serum creatinine &gt; 3.0 mg/dL

          7. History of cirrhosis

          8. LVAD use

          9. Heart failure hospitalization within past month

         10. Acute coronary syndrome, coronary intervention or ablation therapy within past 2
             months or cardiac surgery, percutaneous repair of a valve or septal defect repair
             within the past 6 months

         11. Taking thyroid extract, LT4, LT3, amiodarone, or medication that affects the
             absorption or metabolism of thyroid hormone; gastrointestinal conditions that affect
             the absorption of thyroid hormone

         12. If female, current or planned pregnancy within the timeframe of study participation

         13. Any medical condition that in the opinion of the investigator, will interfere with the
             safe completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R Cappola, MD,ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa M Scattergood, MSN</last_name>
    <phone>215-898-5664</phone>
    <email>theresa.scattergood@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne C Holland, BA</last_name>
    <phone>215-573-0902</phone>
    <email>anne.holland@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PennMedicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa M Scattergood, M.S.N., R.N.</last_name>
      <phone>215-898-5664</phone>
      <email>theresa.scattergood@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Annie C Holland, B.A.</last_name>
      <phone>215-573-0902</phone>
      <email>anne.holland@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Anne Cappola</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure, HFrEF, Low T3 Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

